Press Releases

Press Releases

Search by keywords:

189 Press Releases found

Memorial Sloan Kettering Opens Pediatric CAR T Cell Clinical Trial

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

  • Thursday, April 9, 2015

Some Cancer Clinics Spend Thousands More Per Patient in Medicare Dollars

The quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK).

  • Monday, April 6, 2015

Memorial Sloan Kettering Debuts New Mobile Application for Patients

Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their upcoming appointments, record their medications and symptoms in online diaries, communicate with their healthcare team, and more.

  • Monday, February 23, 2015

Memorial Sloan Kettering Cancer Center and Weill Cornell to Co-Lead Tuberculosis Research Unit

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.

  • Wednesday, February 18, 2015

Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

  • Sunday, December 7, 2014

Positive Data from Pivotal Phase III Study Could Improve Standard of Care for Hodgkin Lymphoma Patients

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

  • Saturday, December 6, 2014

Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients

A number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.

  • Saturday, December 6, 2014

Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures

A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.

  • Wednesday, November 19, 2014

Memorial Sloan Kettering Brings Cancer Care Closer to Home for Hudson Valley Residents

Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.

  • Wednesday, October 1, 2014

New Academic-Industry Partnership Creates Online Registry for Patients Tested for Inherited Cancer Risk

The Prospective Registry Of Multi-Plex Testing (PROMPT) - a new online, volunteer registry for individuals who have been tested for inherited mutations in cancer-causing genes - will provide data vital to improving our understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.

  • Tuesday, September 23, 2014